click on circles to display study description...

Crippa (CANDIDATE), 2021 NCT04467918

Cannabidiol (n=53) vs. placebo (n=52)

randomized controlled trial

Cannabidiol
300mg/day Cannabidiol plus standard of care during 14 days.

Placebo
Placebo plus standard of care during 14 days.

COVID-19 mild to moderate

Double-blind.

2 sites in Sao Paulo, Brazil.

Primary endpoint was measured with the COVID-19 Scale or the natural course of the resolution of typical clinical symptoms, and assessed on days 14, 21, and 28 after enrollment.

VERU-111, 2022 NCT04842747

sabizabulin (n=134) vs. placebo (n=70)

randomized controlled trial

daily oral doses of sabizabulin 9mg for 21 days

placebo

COVID-19 mild to moderate

double-blind

27 centers, worldwide

met the prespecified superiority criterion for efficacy at the time of the interim analysis with 150 patients

planned interim analysis